Target intelligence / Profile preview

MAD2L1-binding protein (MAD2L1BP)

Target
MAD2L1BP
Molecular classification
Other (cell-cycle regulator, spindle assembly checkpoint component, protein-protein interaction regulator)
01

Overview

MAD2L1-binding protein (MAD2L1BP), also known as p31(comet), is a highly conserved protein encoded by the MAD2L1BP gene in humans[1][3][8]. It acts as a crucial regulator of the spindle assembly checkpoint (SAC) during cell division, binding to MAD2 (Mitotic Arrest Deficient 2) after it dissociates from CDC20 and facilitating its disassembly via recruitment of the AAA+-ATPase TRIP13[3][8]. This SAC silencing is essential for the transition from metaphase to anaphase and for faithful chromosome segregation[3][4][8]. Genetic studies have shown that biallelic loss-of-function variants in MAD2L1BP cause severe human disorders, including mosaic variegated aneuploidy syndromes, microcephaly, childhood-onset cancers, and female infertility due to oocyte maturation arrest, highlighting the protein's importance for genomic stability and reproductive health[4][8]. The protein does not belong to classical receptor, enzyme, or transporter superfamilies, but is recognized for its essential adapter function in cell cycle regulation and its protein-protein interactions crucial for SAC silencing and DNA repair[3][8]. There are currently no known drugs targeting MAD2L1BP.

Other names
Caught by MAD2 proteinCMT2KIAA0110dJ261G23.1p31cometp31(comet)MAD2L1BPRP1-261G23.6
02

Mechanism of action

Not established for any approved or investigational drugs (current interventions relate to gene/protein rescue in functional studies, not pharmaceuticals)[8].

03

Biological functions

Cell cycle regulationMitotic checkpoint controlSpindle assembly checkpoint (SAC) silencingChromosome segregationHomology-directed DNA repairCell proliferationMeiosis and oocyte maturation
04

Disease associations

Cancer (tumor predisposition with biallelic mutation)Genetic diseases (microcephaly, epileptic encephalopathy, aneuploidy syndromes)Infertility (oocyte maturation arrest/female infertility)
05

Safety considerations

Theoretical risk in targeting may include disruption of cell division, aneuploidy, infertility, or increased cancer susceptibility due to critical roles in chromosome segregation[4][8].

Beyond the preview

Go deeper on MAD2L1-binding protein (MAD2L1BP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAD2L1-binding protein (MAD2L1BP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call